AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03866577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as intravenous infusion
Trial: NCT00454337
Drug: FTC/TDF + EFV or LPV/R +T20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
Trial: NCT00454337
Drug: FTC/TDF + EFV or LPV/R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
Trial: NCT04259164
Drug: QVM149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
Trial: NCT04259164
Drug: QMF149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone / Indacaterol
Trial: NCT04122300
Drug: Euphrasia Officinalis Preparation
RxNorm normalized name: Euphrasia officinalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Trial: NCT04122300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Trial: NCT00419991
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
Trial: NCT01836471
Drug: Placebo QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
Trial: NCT04708613
Drug: [C-11]6-OH-BTA-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging of the brain using an amyloid ligand.
Trial: NCT04708613
Drug: [F-18]AV-1451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging of the brain using a tau ligand.
Trial: NCT00826969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03119779
Drug: MTA-Anglus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
Trial: NCT03119779
Drug: TheraCal
RxNorm normalized name: TheraCal D2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
Trial: NCT02105987
Drug: ABC/DTG/3TC FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
Trial: NCT02105987
Drug: Ongoing cART regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
Trial: NCT00235755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT04967326
Drug: Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04588168
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
Trial: NCT00858494
Drug: Hyland's Cold 'n Cough 4 Kids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
Trial: NCT01522456
Drug: Retin-A Micro Microsphere 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
Trial: NCT05872789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral gel used on tongue and palate twice daily.
Trial: NCT02566772
Drug: TAS3681
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
Trial: NCT02962648
Drug: Iron isomaltoside/ferric derisomaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.
Trial: NCT05164692
Drug: 0.9% NaCl physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Trial: NCT02291237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match eleclazine administered orally once daily
Trial: NCT02890602
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
Trial: NCT02279966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01709500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Trial: NCT04192643
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ML SALİNE SOLUTİON
Trial: NCT02353182
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
Trial: NCT02047474
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02047474
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01480869
Drug: calcium and cholecalciferol
RxNorm normalized name: calcium phosphate / cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
Trial: NCT01480869
Drug: calcium and cholecalciferol
RxNorm normalized name: calcium phosphate / cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL
Trial: NCT01950455
Drug: NAV5001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Trial: NCT01868802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline at 0.9% intravenous infusion will be administered over 40 minutes.
Trial: NCT04073537
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib blank analog capsule.
Trial: NCT00809562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily for 10 days
Trial: NCT00809562
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
Trial: NCT00550355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses of Placebo administered over 12 weeks
Trial: NCT00616213
Drug: PR104
RxNorm normalized name: PR104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR104 is administered intravenously once every 21 days
Trial: NCT04302870
Drug: Placebo oral solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken once daily
Trial: NCT02206854
Drug: R-flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg gelatine capsule once orally
Trial: NCT02094560
Drug: CAP7.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
Trial: NCT00205179
Drug: Novasoy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/day soy isoflavones
Trial: NCT00205179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/day matching placebo
Trial: NCT00624442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 2 hours
Trial: NCT00624442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 24 hours
Trial: NCT00624442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion for 72 hours
Trial: NCT03760913
Drug: OLP-1002 (Test): Part A, Single Ascending Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
Trial: NCT00412646
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03066609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
Trial: NCT03006367
Drug: NFC-1 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006367
Drug: NFC-1 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006367
Drug: NFC-1 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006367
Drug: NFC-1 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01595789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
Trial: NCT00115089
Drug: R926112
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03032458
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
Trial: NCT02477514
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet administered as a single oral dose on Days 3 and 16
Trial: NCT00930306
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 doses, Given as Tablet, 2x50 mg
Trial: NCT00137098
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00973505
Drug: Aromatase Inhibitor(Femara or Arimidex)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
Trial: NCT04547764
Drug: triple antibiotic paste (TAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: root canal treatment of pulpally involved teeth.
Trial: NCT03809949
Drug: Fentanyl Opioid anesthesia
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
Trial: NCT01302600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1ml/kg once a day with food at dinner.
Trial: NCT01074359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 days of placebo oral capsules. Treatment taken twice daily with meals.
Trial: NCT03282045
Drug: Lysobact Complete Sprey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling spray
Trial: NCT03282045
Drug: Tantum Verde® Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling spray
Trial: NCT03282045
Drug: Pharyngal® Oromucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling spray
Trial: NCT03282045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling spray
Trial: NCT00811941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as-needed use, tablets, orally, 52 weeks
Trial: NCT02061124
Drug: Placebo 1600 mg TID for 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04027439
Drug: Part A: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
Trial: NCT04027439
Drug: Part B: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
Trial: NCT04027439
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.
Trial: NCT03664011
Drug: BI 730357 mixed with [C-14]BI 730357 BS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT04564365
Drug: beta-blocker
RxNorm normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
Trial: NCT04354389
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg b.i.d
Trial: NCT04354389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q.d. or b.i.d.
Trial: NCT04354389
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg q.d.
Trial: NCT00167921
Drug: Premarin® Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00167921
Drug: Premarin® oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03355534
Drug: intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline is given to patients intravenously
Trial: NCT00032435
Drug: PAL-40 Active
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00032435
Drug: PAL-40 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00111683
Drug: MK0457
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00979459
Drug: MK-1006 DFC
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dry filled capsule contains 20 mg MK-1006
Trial: NCT00979459
Drug: MK-1006 FCT
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each film coated tablet contains 40 mg of MK-1006
Trial: NCT01782846
Drug: Ixprim®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01782846
Drug: Dafalgan-Codeine®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01262963
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
Trial: NCT05047458
Drug: ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-in-capsule (PIC).
Trial: NCT05047458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIC.
Trial: NCT01812759
Drug: Fentanyl Nasal Spray
RxNorm normalized name: Fentanyl Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg nasal spray administered in each nostril.
Trial: NCT00360269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 to 100 mg daily
Trial: NCT03407144
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)
Trial: NCT03407144
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Trial: NCT04174079
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
Trial: NCT02359448
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
Trial: NCT03528213
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline at physician discretion
Trial: NCT01146522
Drug: LCQ908
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01146522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03166085
Drug: PU-H71
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
Trial: NCT00890591
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
Trial: NCT01664741
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01420497
Drug: intra-articular infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra articular infiltration
Trial: NCT00010088
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00010088
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00635700
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01440166
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.